UK markets closed

Smith & Nephew plc (SNN)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
33.44+0.99 (+3.04%)
As of 01:16PM EST. Market open.
Sign in to post a message.
  • B
    Cementless knee replacement driving this up.
  • Y
    Yahoo Finance Insights
    Smith & Nephew reached a 52 Week low at 32.30
  • Y
    Yahoo Finance Insights
    Smith & Nephew reached a 52 Week low at 33.02
  • R
    yikes, bearish trend...... but it will bounce back at some point
  • M
    $MESO conversation
    To All New MESO shareholders and stem cell / MESO naysayers – a lot of us long-time shareholders (Minnesota, Left-e, Seanpierre1, Josephine, Frank/ Tarentella 123, Francesca, George, etc..) have been involved with Osiris for a very long time – some as early as the IPO, and others that have bought over the years. I first bought Osiris in 2011 after a lot of research and continued to buy over a period of years. When Osiris partnered with Mesoblast in October 2013, it was a huge disappointment in my mind – but in hindsight, is was a great decision by Peter Friedli. Peter knew that taking Prochymal – Remestemcel-L to market would have required a lot of capital/dilution. This enabled Osiris to focus on Grafix, GrafixPL, Stravix, etc. Peter was excellent at choosing the right partner for Osiris’ technology/science. NuVasive, Inc. $NUVA for Osteocel, Stryker Corporation $SYK for BIO4, Arthrex for BIO4, etc. until Smith & Nephew $SNN bought our Osiris in March of 2019. Peter was a co-founder of the Osiris along with Kevin Kimberlin. I would suggest EVERYONE search Kevin’s website – first and last name together dot com – to understand his background. I know some long term shareholders who had the opportunity to meet Kevin in the past at Osiris’ shareholders meetings. He is a very intelligent individual and his background is VERY IMPRESSIVE. The SCIENCE is ready for PRIME TIME. Anyone looking at the small sample size of the Covid-19 trial – need to look at the past trials and the success to draw any conclusions. Many of us have had the opportunity to tour Osiris’ headquarters in Maryland – their walls were lined with children that were saved by their SCIENCE. That was their motivation! Peter knew when to partner with the right company. We’ll see when/if MESO will partner with big pharma – hopefully it’s north of $75/share. Until then, do your own research and understand the science/history. We’re at a critical stage of stem cell therapies and MESO is the BEST horse in the race. Disclaimer: long a lot of $ATHX too! …. And the $MDXG Cheerleaders deserve a shout out to – you shouldn’t have drank Pete’s Kool-Aid and listened to Beef, Peter, Wendy, Frozen, BrianX, Homebuilder, etc. – they’re all clueless and people that follow them - continue to miss a great opportunity!
  • C
    While the departure is surprising, I can’t see it having much effect on the company’s continued growth. I happily added some shares at this price.
  • C
    Cisco Squid
    Seems that SNN is down most likely because of the virus. People that need replacement parts are waiting until they can get in to hospitals to get the work done. At the end of this virus crisis SNN will do very well. Question is how much further will it drop? Neutral for now.
  • C
    Courtesy of Left-e

    Left-e7 days ago
    In the News:
    Osiris Therapeutics Awarded Patent for Immuno-compatible Chorionic Membrane Products
    Thu Apr 25 09:50:30 2019 EDT
    Alexandria , April 24 -- Osiris Therapeutics has been awarded a patent for immunocompatible chorionic membrane products. This invention was developed by Tom Samson , Danilkovitch Alla, Yoo Dana , Jansen Timothy , Kuang Jin-Qiang and Marconi Jennifer Michelle . The patent application number is 14/291,256. The International Patent Classification codes are A61K 35/50 (20150101), A61K 35/28 (20150101), C12N 5/073 (20100101), A61K 38/18 (20060101), A61K 38/39 (20060101), A61K 38/57 (20060101) and A01N 1/02 (20060101). Cooperative Patent Classification codes are A61K 35/28 (20130101), A01N 1/0221 (20130101), A61K 35/50 (20130101), A61K 38/1825 (20130101), A61K 38/1841 (20130101), A61K 38/39 (20130101), A61K 38/57 (20130101), C12N 5/0605 (20130101), C12N 2500/02 (20130101), C12N 2501/115 (20130101) and C12N 2502/025 (20130101).
    The abstract released by U.S. Patent and Trademark Office states, "Provided herein is a placental product comprising an immuno-compatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment."
  • d
    Darn, it would have been sweet

    In April we
    completed the acquisition of Osiris Therapeutics, Inc., a fast-growing company delivering regenerative medicine products,
    including skin, bone-graft and articular cartilage substitutes. The Osiris portfolio delivered double-digit growth in the quarter
    and we expect it to improve the overall growth outlook for Advanced Wound Bioactives.
  • A
    $LXRP conversation
    “all of them are at or near good points to buy or average down. The names are: 1933 Industries (CSE: $TGIF (OTCQB: TGIFF), Cannabis Growth Opportunity Corp. (CSE: $CGOC , Khiron Life Sciences (TSXV: $KHRN OTCQB: KHRNF), Lexaria (CSE: LXX) (OTCQX: LXRP) and Sunniva (CSE: $SNN (OTCQB: SNNVF). “
    Post | Let's Toke Business Cannabis Investing
  • G
    Geddes Gimps
    This stock should rise if they’re purchasing NuVasive
  • n
    Yeah the hips are selling, that means Zimmer is losing......
  • I
    Invest in Health
    $OSIR conversation
    What happens if we just hold on to OSIR at this point? Will we get cash if the deal goes through, or do our holdings get converted to Smith and Nephew? $SNN?
  • i
    The Small Bone and Joint Orthopedic Devices market in the US was valued at over 2.6 billion by 2020. Currently holding over 2% of the US market, Smith+Nephew will be gaining an estimated 3.9% of Integra LifeSciences’ market share through a new acquisition making the company the sixth leader in the overall small bone and joint market.
  • Y
    Yahoo Finance Insights
    Smith & Nephew is up 12.92% to 41.78
  • Y
    Yahoo Finance Insights
    Smith & Nephew is down 5.58% to 41.26
  • i
  • r
    48$ by October 2021
  • M
    MiMedx Group, Inc.
    I heard a rumor that MiMedx will hire Homebuilder as their PERMANENT CFO. I heard homebuilder has a lot of respect for Ed!

    Source of Rumor - Beef, Wendy, Nancy, Weather, Short, and Scotland. BTW, don't assume there are MULTIPLE sources. It's ONLY ONE with multiple IDS.

    MiMedx is NOW going to get its $@& kicked my $OSIR / $SNN !
  • I
    Invest in Health
    $OSIR conversation
    What is everyone's thoughts on selling vs keeping $SNN stock?
    $SNN looks very profitable, but not much growth... would $OSIR change that?